CRDF - Cardiff Oncology to Present at Upcoming Investor Conferences in September

PR Newswire

SAN DIEGO , Sept. 7, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that Mark Erlander , Ph.D., chief executive officer and James Levine , chief financial officer, of Cardiff Oncology, will present and participate in virtual 1x1 investor meetings at the H.C. Wainwright 23 ^rd Annual Global Investment Conference and the 2021 Cantor Virtual Global Healthcare Conference, taking place September 13 – 15 ^th 2021, and September 27 – 30 ^th 2021, respectively.

Details on the presentations can be found below.

Replays of the presentations will be available by visiting the " Events " section of the Cardiff Oncology website after their conclusion and will be archived for 90 days.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations that overcome disease resistance and improve disease response to standard treatment regimens and to increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 ("PLK1") inhibitor, in combination with standard-of-care anti-cancer therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to refine assessment of patient response to treatment. We have three clinical programs currently ongoing: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® (bevacizumab) in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in metastatic castrate-resistant prostate cancer (mCRPC); and a Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC). For more information, please visit https://www.cardiffoncology.com .

Cardiff Oncology Contact:
Vicki Kelemen
Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Amy Jobe , Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com

SOURCE Cardiff Oncology, Inc.